Table 1.
Overview of some CXCR4/CXCL12 targeting anti-MM compounds.
| Compound | Secondary names | Mechanism of action | Significant clinical trial identifiers | References |
|---|---|---|---|---|
| Plerixafor | AMD3100/ mozobil | CXCR4 antagonist; abrogates CXCL12 induced receptor internalization | NCT00322842 | [6], [66], [68], [95], [123], [124], [125], [126], [127], [128], [129], [151] |
| NCT00322387 | ||||
| Ulocuplumab | BMS-936564/MDX-1338 | Anti-CX43 antibody that affects survival and adhesion of MM cells | NCT01359657 | [21], [139] |
| Burixafor | TG-0054 | CXCR4 antagonist that can block CXCL12 binding; stem cell mobilizer | NCT02104427 | [68], [152], [153] |
| Balixafortide | Polyphor (POL6326) | Inhibits CXCR4-CXCL12 interaction; hematopoietic stem cell mobilizer | NCT01105403 | [68], [127], [153], [154] |
| BKT140 | BL8040/TN14003 | CXCR4 antagonist; induce MM cell apoptosis | NCT01010880 | [6], [132] |
| Panobinostat | LBH589 | CXCR4 inverse antagonist; affect MM cell viability and osteoclast formation | NCT00743288 | [133], [134], [135], [136], [137], [155] |
| NCT00532675 | ||||
| NCT01023308 |